Effectiveness of first-line therapy in patients with advanced non-clear renal cell carcinoma (nccRCC).
Sophie Laramee(McMaster University), Aly‐Khan A. Lalani(Juravinski Cancer Centre), Naveen S. Basappa, Rodney H. Breau(University of Ottawa), Frédéric Pouliot(Université Laval), Ramy Saleh(McGill University Health Centre), Georg A. Bjarnason(Sunnybrook Health Science Centre), Denis Soulières(Centre Hospitalier de l’Université de Montréal), Sunita Ghosh(Tata Memorial Hospital), Lori Wood(Dalhousie University), Vincent Castonguay(Centre hospitalier universitaire de Québec), Christian Kollmannsberger(BC Cancer Agency), Christina M. Canil(University of Ottawa), Anil Kapoor(People’s University), Daniel Yick Chin Heng(University of Calgary), Aaron R. Hansen(Princess Margaret Cancer Centre)
Cited by 2
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I
|European Urology|2008|617
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer
|Cancer Discovery|2018|520
Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline
|The Journal of Urology|2019|482
Exosomes Induce Fibroblast Differentiation into Cancer-Associated Fibroblasts through TGFβ Signaling
|Molecular Cancer Research|2018|322